ClinicalTrials.gg
CompletedNCT05305222Updated Mar 31, 2022

A Study in Healthy Japanese and Caucasian Subjects to Assess the Pharmacokinetics, Safety and Tolerability of Risankizumab

A Phase 1 interventional study of Risankizumab and Placebo in Healthy Volunteers, sponsored by AbbVie. Completed at 1 site in United States. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-03-31.

Sponsored by AbbVie · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Jun 2018, 8 years 5 months ago, and no results have been posted to the registry.
  • Registered 4 years 5 months after the study started (first participant enrolled Oct 2017, registered Mar 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
17
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

The main objective of this study is to assess the pharmacokinetics, safety, tolerability and immunogenicity following a single intravenous (IV) infusion of risankizumab in healthy Japanese and Caucasian participants.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Healthy Volunteers
  • Risankizumab
  • Skyrizi
03

In context

Lead sponsor

AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.

Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must be first or second generation Japanese of full parentage residing outside of Japan for less than 10 years. First generation participants will have been born to two parents and four grandparents also born in Japan of full Japanese descent. Second generation participants born outside of Japan must have two parents and four grandparents born in Japan of full Japanese descent. All participants must maintain a typical Japanese lifestyle, including consuming a typical Japanese diet or participants must be Caucasian and not of Hispanic ethnicity.
  • (BMI) is >= 18.5 and \<= 29.9 kg/m2 (after rounding to the tenths decimal) at Screening. BMI is calculated as weight in kilograms (kg) divided by the square of height measured in meters (m).

Exclusion criteria

Exclusion Criteria:

  • Previous exposure to any anti-IL-12/23 or anti-IL-23 treatment.
  • Any findings in the medical examination that are deviating from normal and judged as by the investigator.
  • Any laboratory value outside the reference range that the investigator considers to be of clinical relevance.
  • Any evidence of a concomitant disease judged as clinically relevant by the investigator.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    Japanese Participants Receiving Risankizumab

    Participants will receive single dose of risankizumab.

    Drug: Risankizumab

  • Experimental
    Japanese Participants Receiving Placebo

    Participants will receive single dose of placebo.

    Drug: Placebo

  • Experimental
    Caucasian Participants Receiving Risankizumab

    Participants will receive single dose of risankizumab.

    Drug: Risankizumab

  • Experimental
    Caucasian Participants Receiving Placebo

    Participants will receive single dose of placebo.

    Drug: Placebo

Interventions

  • Intravenous (IV) Infusion

    Also known as: SKYRIZI, ABBV-066

  • DrugPlacebo

    Intravenous (IV) Infusion

06

What researchers measure

Primary outcomes

  1. Number of Participants Experiencing Adverse Events

    An adverse event is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.

    Time frame: Up to approximately 137 days

  2. Maximum Observed Plasma Concentration (Cmax) of Risankizumab

    Maximum observed plasma concentration (Cmax) of Risankizumab.

    Time frame: Up to approximately 137 days

  3. Time to Cmax (Cmax) of Risankizumab

    Tmax of Risankizumab.

    Time frame: Up to approximately 137 days

  4. Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to the Last Measurable Concentration (AUCt) of Risankizumab

    AUCt of Risankizumab.

    Time frame: Up to approximately 137 days

  5. Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to Infinity (AUCinf) of Risankizumab

    AUCinf of Risankizumab.

    Time frame: Up to approximately 137 days

  6. Apparent Terminal Phase Elimination Rate Constant (β) of Risankizumab

    Apparent terminal phase elimination rate constant (β) of Risankizumab.

    Time frame: Up to approximately 137 days

  7. Terminal Phase Elimination Half-life (t1/2) of Risankizumab

    Terminal phase elimination half-life (t1/2) of Risankizumab.

    Time frame: Up to approximately 137 days

07

Study locations

1 site
  • Altasciences Clinical Los Angeles, Inc /ID# 164197
    Cypress, California 90630, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2017 to primary completion in Jun 2018, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2022
First posted
Mar 31, 2022
StartActual
Oct 23, 2017
Primary completionActual
Jun 15, 2018
CompletionActual
Jun 15, 2018
Last update
Mar 31, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 31, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05305222
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Mar 31, 2022
Start date
Oct 23, 2017
Primary completion
Jun 15, 2018
Completion
Jun 15, 2018
Last update
Mar 31, 2022

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Risankizumab

Start the discussion